title: [Lenalidomide nephrotoxicity].
abstract: The introduction of lenalidomide into the therapeutic arsenal of hematologic malignancies has represented an important step forward in the management of multiple myeloma. However, its use is associated with several toxicities including kidney injury. The present review examines the drug's pharmacokinetics, discusses the main adverse renal effects that are associated with lenalidomide treatment, and makes recommendations for dosage adjustment in patients with underlying renal impairment.
authors.affiliation: La Rabta Hospital, service de néphrologie, Tunis, Tunisie.
authors.forename: Rania
authors.initials: R
authors.lastname: Kheder El-Fekih
authors.affiliation: Clinique internationale du Parc Monceau (CIPM), 21, rue de Chazelles, 75017 Paris, France. Electronic address: hassan.izzedine@clinique-monceau.com.
authors.forename: Hassan
authors.initials: H
authors.lastname: Izzedine
mesh_terms: D006086:Graft vs Host Disease / Q000139:chemically induced / Q000276:immunology; D006801:Humans; D007155:Immunologic Factors / Q000008:administration & dosage / Q000009:adverse effects* / Q000493:pharmacokinetics; D007668:Kidney / Q000187:drug effects* / Q000473:pathology; D007684:Kidney Tubules / Q000187:drug effects / Q000473:pathology; D000077269:Lenalidomide; D009336:Necrosis / Q000139:chemically induced; D009395:Nephritis, Interstitial / Q000139:chemically induced; D015995:Prevalence; D051437:Renal Insufficiency / Q000453:epidemiology / Q000378:metabolism; D013792:Thalidomide / Q000008:administration & dosage / Q000009:adverse effects / Q000031:analogs & derivatives* / Q000493:pharmacokinetics
chemical_list: D007155:Immunologic Factors; D013792:Thalidomide; D000077269:Lenalidomide
keywords: Acute interstitial nephritis; Acute kidney injury; Adverse event; Effets indésirables; Insuffisance rénale aiguë; Lenalidomide; Lénalidomide; Multiple myeloma; Myélome multiple; Nephrotoxicity; Néphrite interstitielle aiguë; Néphrotoxicité; Rhabdomyolyse; Rhabdomyolysis